$106.41
0.85% yesterday
Nasdaq, Apr 23, 10:00 pm CET
ISIN
US3755581036
Symbol
GILD
Sector
Industry

Gilead Sciences Stock price

$106.38
-0.36 0.34% 1M
+19.15 21.95% 6M
+14.01 15.17% YTD
+39.35 58.71% 1Y
+43.73 69.80% 3Y
+28.60 36.77% 5Y
+1.18 1.12% 10Y
Nasdaq, Closing price Wed, Apr 23 2025
+0.87 0.82%
ISIN
US3755581036
Symbol
GILD
Sector
Industry

Key metrics

Market capitalization $132.62b
Enterprise Value $148.29b
P/E (TTM) P/E ratio 289.78
EV/FCF (TTM) EV/FCF 14.39
EV/Sales (TTM) EV/Sales 5.16
P/S ratio (TTM) P/S ratio 4.62
P/B ratio (TTM) P/B ratio 6.86
Dividend yield 2.90%
Last dividend (FY24) $3.08
Revenue growth (TTM) Revenue growth 6.16%
Revenue (TTM) Revenue $28.73b
EBIT (operating result TTM) EBIT $10.66b
Free Cash Flow (TTM) Free Cash Flow $10.31b
Cash position $11.57b
EPS (TTM) EPS $0.37
P/E forward 17.10
P/S forward 4.62
EV/Sales forward 5.16
Short interest 1.72%
Show more

Create a Free Account to create an Gilead Sciences alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Gilead Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Gilead Sciences forecast:

19x Buy
63%
10x Hold
33%
1x Sell
3%

Analyst Opinions

30 Analysts have issued a Gilead Sciences forecast:

Buy
63%
Hold
33%
Sell
3%

Financial data from Gilead Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
28,727 28,727
6% 6%
100%
- Direct Costs 6,251 6,251
5% 5%
22%
22,476 22,476
7% 7%
78%
- Selling and Administrative Expenses 3,234 3,234
5% 5%
11%
- Research and Development Expense 5,814 5,814
0% 0%
20%
13,428 13,428
13% 13%
47%
- Depreciation and Amortization 2,767 2,767
3% 3%
10%
EBIT (Operating Income) EBIT 10,661 10,661
16% 16%
37%
Net Profit 480 480
92% 92%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Gilead Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gilead Sciences Stock News

Positive
Reuters
3 days ago
Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an aggressive type of breast cancer.
Neutral
Business Wire
3 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally ad...
Neutral
Business Wire
14 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2025 financial results and provide a business upda...
More Gilead Sciences News

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Head office United States
CEO Daniel O'Day
Employees 17,600
Founded 1987
Website www.gilead.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today